How is India Moving Ahead with Emerging Infectious Disease Diagnostics?

The diagnostic sector for emerging infectious diseases in India encompasses a variety of ailments including respiratory, sexually transmitted, gastrointestinal, neurological, and post-transplant infections, along with sepsis and antimicrobial resistance (AMR). Contrary to numerous other nations with low to middle incomes, India continues to experience a significant occurrence of infectious diseases.?

Moreover, there's an escalating trend of non-communicable diseases (NCDs) too. This scenario places a dual health burden on families across the nation. The ensuing segment discusses the frequency, rate of diagnosis, and the focus group of patients for diverse infectious diseases within India.

Rising Infectious Diseases in India

India has witnessed a surge in infectious diseases. Respiratory diseases such as Influenza A and B, and gastrointestinal diseases like Peptic Ulcer are expected to witness a diagnosis rate as high as 30%.? The emergence of new infectious diseases also poses a significant threat. The dense population and sometimes inadequate healthcare infrastructure contribute to the rapid spread of these diseases, making timely and accurate diagnostics crucial.

Additionally, the COVID-19 pandemic has underscored the importance of having robust diagnostic systems in place. The capacity to swiftly identify and respond to emerging infectious threats is essential to mitigate their impact. Enhanced diagnostic solutions are pivotal in controlling the spread of infectious diseases and safeguarding public health.

Infectious Disease Diagnostic Market Dynamics in India

The diagnostic market in India is evolving with advancements in molecular diagnostics, rapid testing kits, and AI-driven diagnostic solutions. Rapid antigen test (RAT), Polymerase chain reaction (PCR) test, and Next-Generation Sequence (NGS) tests are the most preferred platforms for infectious disease diagnostics. Moreover, the growing awareness among the populace about early diagnosis is further propelling the growth of this market.

The adoption of point-of-care testing (POCT) is significantly advancing the emerging infectious disease diagnostics market in India, providing rapid, on-site diagnosis crucial for timely medical intervention in a densely populated region. Recent developments include pharmaceutical giant Cipla Health Ltd 's launch of Cippoint, a POCT device for diverse clinical applications including infectious diseases, in January 2023. Furthermore, the Indian Council of Medical Research (ICMR) announced in June 2023 that it's developing seven syndromic test kits to diagnose respiratory illnesses by detecting both viral and bacterial pathogens.?

Public and private sectors are increasingly investing in diagnostic services to improve healthcare outcomes. Global collaborations have played a pivotal role in bolstering the diagnostic capabilities in India. These dynamics indicate a positive trajectory for the infectious disease diagnostic market, with a potential for significant growth and innovation.

For more insights on India Infectious disease diagnostics market, visit: https://bit.ly/3sdXuxp

Private initiatives and Public Policy around the Infectious Disease Diagnostic

The emerging infectious disease diagnostics market in India has seen a boost through various initiatives by government bodies and organizations, aiming to heighten awareness and readiness toward infectious diseases. Notable among these initiatives is the National Diagnostics Catapult (C-CAMP InDx 2.0) launched by the Centre for Cellular and Molecular Platforms (C-CAMP) in February 2023, designed to prepare India for current and future pandemics and strengthen the diagnostics sector for infectious diseases.?

In line with these efforts, several companies have secured funding to advance diagnostic technologies. For instance, Indian startup D-NOME Pvt. Ltd. raised $1.5 million in January 2023 for rapid point-of-care diagnostics development, while Molbio Diagnostics garnered $85.0 million in September 2022 to commercialize a portable real-time PCR device capable of testing over 40 infectious diseases. Additionally, Cardea Bio (part of Paragraf?) and 西门子医疗 AG announced a? collaboration in January 2022 to explore the feasibility of real-time molecular diagnostic applications, showcasing a collaborative endeavor toward bolstering the infectious disease diagnostics landscape in India.

Future of India Infectious Disease Diagnostics

The landscape of infectious disease diagnostics in India is on a positive trajectory, with technological advancements and policy measures aligning to address the challenges head-on. The evolving diagnostic market dynamics indicate a promising future in combating infectious diseases and reducing the disease burden in the country.

However, a collaborative effort among government bodies, private sectors, and global health organizations is imperative to further accelerate the progress in this realm. By fostering innovation and ensuring accessibility and affordability of diagnostic services, India can significantly mitigate the impact of infectious diseases and enhance public health outcomes.

Interested to know more about the growing technologies in your industry vertical? Get the latest market studies and insights from BIS Research. Connect with us at [email protected] to learn and understand more.